Follow this preprint

Cardiovascular Eligibility Criteria and Adverse Event Reporting in Cancer Therapy Trials of Combined Immune Checkpoint and VEGF Inhibitors: A Systematic Review

Stephen Rankin, Benjamin Elyan, Robert Jones, Balaji Venugopal, Patrick B Mark, Jennifer S Lees, Mark C Petrie, Ninian N Lang
doi: https://doi.org/10.1101/2023.07.14.23292585
This article is a preprint and has not been peer-reviewed [what does this mean?]. It reports new medical research that has yet to be evaluated and so should not be used to guide clinical practice.

Data Availability

original data can be made available on request.

Back to top
Posted July 16, 2023.
Download PDF
Print/Save Options
Download PDFFull Text & In-line FiguresXML

Supplementary Material

Data/Code
Email
Cardiovascular Eligibility Criteria and Adverse Event Reporting in Cancer Therapy Trials of Combined Immune Checkpoint and VEGF Inhibitors: A Systematic Review
Stephen Rankin, Benjamin Elyan, Robert Jones, Balaji Venugopal, Patrick B Mark, Jennifer S Lees, Mark C Petrie, Ninian N Lang
medRxiv 2023.07.14.23292585; doi: https://doi.org/10.1101/2023.07.14.23292585
This article is a preprint and has not been peer-reviewed [what does this mean?]. It reports new medical research that has yet to be evaluated and so should not be used to guide clinical practice.
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area

Reviews and Context

0

Comment

0

TRIP Peer Reviews

0

Community Reviews

0

Automated Services

0

Blogs/Media

0

Author Videos

You can now receive automatic notifications when a preprint is revised, withdrawn, commented on, peer reviewed, or published in a journal. Select the events you would like to follow below and click "Submit". To see all of the preprints you are currently following, please go to the medRxiv Alerts Page.

Sign In to Follow this Preprint

We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.